Education
About Us
Working with TipRanks
Follow Us
Biodexa Pharmaceuticals (BDRX)
NASDAQ:BDRX
RESEARCH TOOLSreports
BDRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.14 - $73.98
Previous CloseN/A
Volume6.04K
Average Volume (3M)3.06M
Market Cap
$3.74M
Enterprise Value$1.53M
Total Cash (Recent Filing)£30.32M
Total Debt (Recent Filing)£1.94M
Price to Earnings (P/E)―
Beta1.55
Next Earnings
Sep 11, 2025EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-17.42
Shares Outstanding2,561,741
10 Day Avg. Volume2,330,658
30 Day Avg. Volume3,061,845
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)9.57
Price to Cash Flow (P/CF)-0.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$18.00Price Target Upside1132.88% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
---
Biodexa Pharmaceuticals News
---
Ownership Overview
11.77%
Insiders
<0.01%
Mutual Funds
<0.01% Other Institutional Investors
88.23% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
BDRX FAQ
What was Biodexa Pharmaceuticals’s price range in the past 12 months?
Biodexa Pharmaceuticals lowest stock price was $1.14 and its highest was $73.97 in the past 12 months.
What is Biodexa Pharmaceuticals’s market cap?
Biodexa Pharmaceuticals’s market cap is $3.74M.
When is Biodexa Pharmaceuticals’s upcoming earnings report date?
Biodexa Pharmaceuticals’s upcoming earnings report date is Sep 11, 2025 which is in 146 days.
How were Biodexa Pharmaceuticals’s earnings last quarter?
Biodexa Pharmaceuticals released its earnings results on Apr 11, 2025. The company reported -$4.647 earnings per share for the quarter, missing the consensus estimate of -$0.001 by -$4.646.
Is Biodexa Pharmaceuticals overvalued?
According to Wall Street analysts Biodexa Pharmaceuticals’s price is currently Undervalued.
Does Biodexa Pharmaceuticals pay dividends?
Biodexa Pharmaceuticals does not currently pay dividends.
What is Biodexa Pharmaceuticals’s EPS estimate?
Biodexa Pharmaceuticals’s EPS estimate is >-0.01.
How many shares outstanding does Biodexa Pharmaceuticals have?
Biodexa Pharmaceuticals has 2,561,741 shares outstanding.
What happened to Biodexa Pharmaceuticals’s price movement after its last earnings report?
Biodexa Pharmaceuticals reported an EPS of -$4.647 in its last earnings report, missing expectations of -$0.001. Following the earnings report the stock price went up 12.739%.
Which hedge fund is a major shareholder of Biodexa Pharmaceuticals?
Currently, no hedge funds are holding shares in BDRX
---
Company Description
Biodexa Pharmaceuticals
Biodexa Pharmaceuticals Plc, a drug delivery technology company, focuses on the bio-delivery and biodistribution of medicines in Belgium and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTX223, a long-acting injectable formulations of biologic products, such as mAbs or other high molecular weight proteins. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
---
BDRX Stock 12 Month Forecast
Average Price Target
$18.00
▲(1132.88% Upside)
Technical Analysis
Best Analysts Covering BDRX
1 Year
1 Year Success Rate
0/2 ratings generated profit
1 Year Average Return
-72.05%
reiterated a buy rating 4 months ago
Copying Aydin Huseynov's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -72.05% per trade.
---